ArticlePLATINUM BASED VERSUS ANTHRACYCLIN BASED NEOADJUVANT CHEMOTHERAPY IN NONMETASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS
ArticlePLATINUM BASED VERSUS ANTHRACYCLIN BASED NEOADJUVANT CHEMOTHERAPY IN NONMETASTATIC TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS
ArticleA retrospective study of the effect of neoadjuvant chemotherapy as a primary treatment of advanced breast cancer and its effect on surgical modalities.
ArticleA retrospective study of the effect of neoadjuvant chemotherapy as a primary treatment of advanced breast cancer and its effect on surgical modalities.
ArticleThe Effect of Neoadjuvant Chemotherapy on Her-2 Status in Her-2 Negative Breast Cancer Patients: A Study on Pathological Response
ArticleThe Effect of Neoadjuvant Chemotherapy on Her-2 Status in Her-2 Negative Breast Cancer Patients: A Study on Pathological Response
ArticleA RETROSPECTIVE ANALYSIS OF CLINICOPATHOLOGICAL DATA AND OUTCOMES OF HORMONAL POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER PATIENTS IN CLINICAL ONCOLOGY DEPARTMENT IN AIN SHAM
ArticleA RETROSPECTIVE ANALYSIS OF CLINICOPATHOLOGICAL DATA AND OUTCOMES OF HORMONAL POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER PATIENTS IN CLINICAL ONCOLOGY DEPARTMENT IN AIN SHAM
ArticleRETROSPECTIVE STUDY OF THE IMPACT OF NEOADJUVANT THERAPY ON SURGICAL DECISIONS IN PATIENTS WITH BREAST CANCER
ArticleRETROSPECTIVE STUDY OF THE IMPACT OF NEOADJUVANT THERAPY ON SURGICAL DECISIONS IN PATIENTS WITH BREAST CANCER
ArticleAssessment Study in Breast Conservative surgery in Locally Advanced Breast Cancer after Good Response to Neoadjuvant Chemotherapy
ArticleAssessment Study in Breast Conservative surgery in Locally Advanced Breast Cancer after Good Response to Neoadjuvant Chemotherapy
ArticleRESPONSE OF LOCALY ADVANCED BREAST CANCER TO PRIMARY CHEMOTHERAPY; IS IT ELIGIBLE FOR BREAST CONSERVATION
ArticleRESPONSE OF LOCALY ADVANCED BREAST CANCER TO PRIMARY CHEMOTHERAPY; IS IT ELIGIBLE FOR BREAST CONSERVATION
ArticleCisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine as First-Line Therapy for Metastatic Triple Negative Breast Cancer
ArticleCisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine as First-Line Therapy for Metastatic Triple Negative Breast Cancer